Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 2/2010

01.03.2010 | Original Article

Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women

verfasst von: Itsuo Gorai, Yaku Tanaka, Shin Hattori, Yasuhisa Iwaoki

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Patients who are diagnosed with osteoporosis and beginning treatment often discontinue their osteoporosis medication relatively early after the start of treatment because of their poor recognition of fracture risk and the asymptomatic nature of osteoporosis. In this study we aimed to assess adherence to treatment with 1 μg alfacalcidol (D), 60 mg raloxifene (R) or a combination of both (D + R) for 1 year in postmenopausal Japanese women with osteoporosis or osteopenia. We defined persistence of D and R as continuing to take tablets for more than 7 of any 14 days immediately before the 1-year visit. A total of 137 subjects aged 49–81 years [64.9 ± 7.0 years, 16.0 ± 12.7 years since menopause (YSM)] were randomly assigned to each treatment group. The proportions persisting with each treatment group at 1 year were 61.4, 65.3, 55.1% for D, R and D + R groups, respectively whereas the compliance to each therapy as judged by the medical possession ratio (MPR) at 1 year were 77.5, 93.8, 78.4%, respectively. There were no significant differences in persistence, compliance and the number of subjects who discontinued treatment due to adverse events among each group. We found significant inverse correlations in percent changes at 1 year between compliance and serum BAP in R and D + R groups or urinary (u-) CTX in the R group. The changes in the level of serum BAP and u-CTX were significantly higher in high-compliance patients (MPR > 80%) treated with raloxifene alone or concomitantly with alfacalcidol compared to those in low-compliance patients.
Literatur
1.
Zurück zum Zitat Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Inn Med 115:209–216 Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Inn Med 115:209–216
2.
Zurück zum Zitat Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with residronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:P297 Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with residronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:P297
3.
Zurück zum Zitat Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 14:965–968CrossRef Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 14:965–968CrossRef
4.
Zurück zum Zitat Caro JJ, Ishak KJ, Huybrechits KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008CrossRef Caro JJ, Ishak KJ, Huybrechits KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008CrossRef
5.
Zurück zum Zitat Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 18:1023–1031CrossRef Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 18:1023–1031CrossRef
6.
Zurück zum Zitat Gorai I, Chaki O, Taguchi Y et al (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1-alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1-alpha-OH-vitamin D3. Calcif Tissue Int 65:16–22CrossRefPubMed Gorai I, Chaki O, Taguchi Y et al (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1-alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1-alpha-OH-vitamin D3. Calcif Tissue Int 65:16–22CrossRefPubMed
7.
Zurück zum Zitat O’Donnell S, Moher D, Thomas K et al (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531–542CrossRefPubMed O’Donnell S, Moher D, Thomas K et al (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531–542CrossRefPubMed
8.
Zurück zum Zitat Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425–434CrossRefPubMed Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425–434CrossRefPubMed
9.
Zurück zum Zitat Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporosis Int 18:1311–1317CrossRef Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporosis Int 18:1311–1317CrossRef
10.
Zurück zum Zitat Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed
11.
Zurück zum Zitat Slemenda CW, Longcope CL, Peacock M, Hui SL, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14–21CrossRefPubMed Slemenda CW, Longcope CL, Peacock M, Hui SL, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14–21CrossRefPubMed
12.
Zurück zum Zitat Gorai I, Chaki O, Nakayama M, Minaguchi H (1995) Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100–104CrossRefPubMed Gorai I, Chaki O, Nakayama M, Minaguchi H (1995) Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100–104CrossRefPubMed
13.
Zurück zum Zitat Blackburn GF, Shah HP, Kenten JH, Leland R, Kamin RA, Kink J, Peterman J, Powell MJ, Shah A, Talley DB, Tyagi SK, Wilkins E, Wu T-G, Massey RJ (1991) Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnosis. Clin Chem 37:1534–1539PubMed Blackburn GF, Shah HP, Kenten JH, Leland R, Kamin RA, Kink J, Peterman J, Powell MJ, Shah A, Talley DB, Tyagi SK, Wilkins E, Wu T-G, Massey RJ (1991) Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnosis. Clin Chem 37:1534–1539PubMed
14.
Zurück zum Zitat Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702PubMed Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702PubMed
15.
Zurück zum Zitat Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123CrossRefPubMed Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123CrossRefPubMed
16.
17.
Zurück zum Zitat Siris E, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed Siris E, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed
18.
Zurück zum Zitat Zanchetta JR, Hakim C, Lombas C (2004) Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res Clin Exp 65:470–480CrossRef Zanchetta JR, Hakim C, Lombas C (2004) Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res Clin Exp 65:470–480CrossRef
19.
Zurück zum Zitat Rossini M, Bianchi G, Munno ODi et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 17:914–921CrossRef Rossini M, Bianchi G, Munno ODi et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 17:914–921CrossRef
20.
Zurück zum Zitat Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008CrossRef Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008CrossRef
21.
Zurück zum Zitat Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed
22.
Zurück zum Zitat Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155–1167CrossRefPubMed Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155–1167CrossRefPubMed
23.
Zurück zum Zitat Reginster J-Y, Collette J, Nerprez A et al (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836CrossRefPubMed Reginster J-Y, Collette J, Nerprez A et al (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836CrossRefPubMed
Metadaten
Titel
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
verfasst von
Itsuo Gorai
Yaku Tanaka
Shin Hattori
Yasuhisa Iwaoki
Publikationsdatum
01.03.2010
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 2/2010
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-009-0112-4

Weitere Artikel der Ausgabe 2/2010

Journal of Bone and Mineral Metabolism 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.